Trade Tonix Pharmaceuticals Holding Corp. - TNXP CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.05 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Tonix Pharmaceuticals Holding Corp ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 0.38 |
Open* | 0.39 |
1-Year Change* | -2.5% |
Day's Range* | 0.39 - 0.4 |
52 wk Range | 0.27-8.31 |
Average Volume (10 days) | 2.04M |
Average Volume (3 months) | 30.75M |
Market Cap | 15.83M |
P/E Ratio | -100.00K |
Shares Outstanding | 58.61M |
Revenue | 3.99M |
EPS | -11.21 |
Dividend (Yield %) | N/A |
Beta | 2.26 |
Next Earnings Date | Mar 11, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Jan 3, 2024 | 0.40 | 0.01 | 2.56% | 0.39 | 0.40 | 0.39 |
Jan 2, 2024 | 0.38 | 0.00 | 0.00% | 0.38 | 0.40 | 0.37 |
Dec 28, 2023 | 0.38 | -0.01 | -2.56% | 0.39 | 0.39 | 0.38 |
Dec 27, 2023 | 0.39 | 0.00 | 0.00% | 0.39 | 0.39 | 0.39 |
Dec 26, 2023 | 0.38 | 0.00 | 0.00% | 0.38 | 0.38 | 0.38 |
Dec 21, 2023 | 0.38 | -0.02 | -5.00% | 0.40 | 0.40 | 0.38 |
Dec 20, 2023 | 0.39 | -0.22 | -36.07% | 0.61 | 0.64 | 0.38 |
Dec 19, 2023 | 0.58 | -0.08 | -12.12% | 0.66 | 0.66 | 0.51 |
Dec 18, 2023 | 0.65 | 0.07 | 12.07% | 0.58 | 0.66 | 0.57 |
Dec 15, 2023 | 0.56 | 0.05 | 9.80% | 0.51 | 0.56 | 0.50 |
Dec 14, 2023 | 0.50 | 0.09 | 21.95% | 0.41 | 0.50 | 0.41 |
Dec 13, 2023 | 0.40 | 0.01 | 2.56% | 0.39 | 0.40 | 0.39 |
Dec 12, 2023 | 0.39 | 0.01 | 2.63% | 0.38 | 0.39 | 0.38 |
Dec 11, 2023 | 0.38 | -0.01 | -2.56% | 0.39 | 0.39 | 0.38 |
Dec 8, 2023 | 0.38 | 0.00 | 0.00% | 0.38 | 0.39 | 0.38 |
Dec 7, 2023 | 0.39 | -0.04 | -9.30% | 0.43 | 0.43 | 0.39 |
Dec 6, 2023 | 0.44 | -0.03 | -6.38% | 0.47 | 0.47 | 0.40 |
Dec 5, 2023 | 0.45 | -0.02 | -4.26% | 0.47 | 0.48 | 0.45 |
Dec 4, 2023 | 0.45 | -0.06 | -11.76% | 0.51 | 0.53 | 0.44 |
Dec 1, 2023 | 0.50 | 0.00 | 0.00% | 0.50 | 0.50 | 0.49 |
Tonix Pharmaceuticals Holding Corp. Events
Time (UTC) | Country | Event |
---|---|---|
Friday, May 3, 2024 | ||
Time (UTC) 15:00 | Country US
| Event Tonix Pharmaceuticals Holding Corp Annual Shareholders Meeting Tonix Pharmaceuticals Holding Corp Annual Shareholders MeetingForecast -Previous - |
Monday, May 6, 2024 | ||
Time (UTC) 12:30 | Country US
| Event Q1 2024 Tonix Pharmaceuticals Holding Corp Earnings Release Q1 2024 Tonix Pharmaceuticals Holding Corp Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 112.091 | 92.312 | 50.511 | 28.828 | 26.322 |
Selling/General/Admin. Expenses, Total | 30.215 | 23.474 | 14.354 | 10.636 | 8.764 |
Research & Development | 81.876 | 68.838 | 36.157 | 18.192 | 17.558 |
Operating Income | -112.091 | -92.312 | -50.511 | -28.828 | -26.322 |
Interest Income (Expense), Net Non-Operating | 1.873 | 0.025 | 0.048 | 0.21 | 0.233 |
Net Income Before Taxes | -110.218 | -92.287 | -50.463 | -28.618 | -26.089 |
Net Income After Taxes | -110.218 | -92.287 | -50.463 | -28.618 | -26.089 |
Net Income Before Extra. Items | -110.218 | -92.287 | -50.463 | -28.618 | -26.089 |
Net Income | -110.218 | -92.287 | -50.463 | -28.618 | -26.089 |
Income Available to Common Excl. Extra. Items | -116.877 | -92.287 | -52.174 | -31.092 | -29.355 |
Income Available to Common Incl. Extra. Items | -116.877 | -92.287 | -52.174 | -31.092 | -29.355 |
Diluted Net Income | -116.877 | -92.287 | -52.174 | -31.092 | -29.355 |
Diluted Weighted Average Shares | 5.71825 | 1.80108 | 0.47296 | 0.00804 | 0.00055 |
Diluted EPS Excluding Extraordinary Items | -20.4393 | -51.2399 | -110.314 | -3865.8 | -53623 |
Diluted Normalized EPS | -20.4393 | -51.2399 | -110.314 | -3865.8 | -53623 |
Total Extraordinary Items | |||||
Dividends per Share - Common Stock Primary Issue | |||||
Total Adjustments to Net Income | -6.659 | 0 | -1.711 | -2.474 | -3.266 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 0 | 0 | 0 | 0 | 0 |
Total Operating Expense | 29.002 | 33.902 | 32.728 | 29.591 | 23.336 |
Selling/General/Admin. Expenses, Total | 7.026 | 7.391 | 8.054 | 7.39 | 6.757 |
Research & Development | 21.976 | 26.511 | 24.674 | 22.201 | 16.579 |
Operating Income | -29.002 | -33.902 | -32.728 | -29.591 | -23.336 |
Interest Income (Expense), Net Non-Operating | 0.646 | 0.897 | 1.048 | 0.61 | 0.196 |
Net Income Before Taxes | -28.356 | -33.005 | -31.68 | -28.981 | -23.14 |
Net Income After Taxes | -28.356 | -33.005 | -31.68 | -28.981 | -23.14 |
Net Income Before Extra. Items | -28.356 | -33.005 | -31.68 | -28.981 | -23.14 |
Net Income | -28.356 | -33.005 | -31.68 | -28.981 | -23.14 |
Income Available to Common Excl. Extra. Items | -28.356 | -33.005 | -34.084 | -28.981 | -27.395 |
Income Available to Common Incl. Extra. Items | -28.356 | -33.005 | -34.084 | -28.981 | -27.395 |
Diluted Net Income | -28.356 | -33.005 | -34.084 | -28.981 | -27.395 |
Diluted Weighted Average Shares | 10.5871 | 10.1365 | 9.88108 | 6.71109 | 3.5847 |
Diluted EPS Excluding Extraordinary Items | -2.67835 | -3.25607 | -3.44942 | -4.31838 | -7.6422 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -2.67835 | -3.25607 | -3.44942 | -4.31838 | -7.6422 |
Total Adjustments to Net Income | 0 | -2.404 | 0 | -4.255 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 130.777 | 189.049 | 87.989 | 13.948 | 26.056 |
Cash and Short Term Investments | 120.229 | 178.66 | 77.068 | 11.249 | 25.034 |
Cash & Equivalents | 120.229 | 178.66 | 77.068 | 11.249 | 25.034 |
Short Term Investments | |||||
Prepaid Expenses | 10.548 | 10.389 | 10.921 | 2.699 | 1.022 |
Total Assets | 225.69 | 240.9 | 98.183 | 14.558 | 26.319 |
Property/Plant/Equipment, Total - Net | 94.529 | 51.472 | 9.829 | 0.39 | 0.043 |
Property/Plant/Equipment, Total - Gross | 96.182 | 51.872 | 10.179 | 0.713 | 0.34 |
Accumulated Depreciation, Total | -1.653 | -0.4 | -0.35 | -0.323 | -0.297 |
Intangibles, Net | 0.12 | 0.12 | 0.12 | 0.12 | |
Other Long Term Assets, Total | 0.384 | 0.259 | 0.245 | 0.1 | 0.1 |
Total Current Liabilities | 18.18 | 21.716 | 9.819 | 5.135 | 2.655 |
Accounts Payable | 8.068 | 13.282 | 4.598 | 3.07 | 1.404 |
Accrued Expenses | 6.18 | 4.929 | 2.6 | 1.042 | 0.614 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 18.508 | 22.183 | 10.535 | 5.141 | 2.655 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0.328 | 0.467 | 0.716 | 0.006 | 0 |
Total Equity | 207.182 | 218.717 | 87.648 | 9.417 | 23.664 |
Common Stock | 0.076 | 0.496 | 0.206 | 0.009 | 0.003 |
Additional Paid-In Capital | 677.311 | 578.133 | 355.037 | 226.524 | 212.154 |
Retained Earnings (Accumulated Deficit) | -470.038 | -359.82 | -267.533 | -217.07 | -188.452 |
Other Equity, Total | -0.167 | -0.092 | -0.062 | -0.046 | -0.041 |
Total Liabilities & Shareholders’ Equity | 225.69 | 240.9 | 98.183 | 14.558 | 26.319 |
Total Common Shares Outstanding | 12.2366 | 2.48123 | 1.03004 | 0.04266 | 0.00163 |
Other Current Liabilities, Total | 3.932 | 3.505 | 2.621 | 1.023 | 0.637 |
Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
---|---|---|---|---|---|
Total Current Assets | 31.337 | 51.329 | 83.726 | 130.777 | 151.139 |
Cash and Short Term Investments | 6.914 | 25.617 | 71.975 | 120.229 | 139.978 |
Cash & Equivalents | 6.914 | 25.617 | 71.975 | 120.229 | 139.978 |
Prepaid Expenses | 9.544 | 12.012 | 11.751 | 10.548 | 11.161 |
Total Assets | 139.282 | 159.736 | 179.088 | 225.69 | 242.646 |
Property/Plant/Equipment, Total - Net | 95.947 | 96.93 | 94.977 | 94.529 | 91.147 |
Property/Plant/Equipment, Total - Gross | 100.342 | 100.397 | 97.523 | 96.182 | 91.964 |
Accumulated Depreciation, Total | -4.395 | -3.467 | -2.546 | -1.653 | -0.817 |
Intangibles, Net | 9.982 | 10.22 | |||
Other Long Term Assets, Total | 1.051 | 0.292 | 0.385 | 0.384 | 0.36 |
Total Current Liabilities | 17.733 | 18.442 | 13.073 | 18.18 | 13.34 |
Accounts Payable | 7.799 | 7.673 | 8.016 | 8.068 | 4.556 |
Accrued Expenses | 9.934 | 10.769 | 5.057 | 10.112 | 8.784 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 18.449 | 19.273 | 13.661 | 18.508 | 13.722 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 0.716 | 0.831 | 0.588 | 0.328 | 0.382 |
Total Equity | 120.833 | 140.463 | 165.427 | 207.182 | 228.924 |
Common Stock | 0.018 | 0.011 | 0.064 | 0.076 | 0.053 |
Additional Paid-In Capital | 694.371 | 686.025 | 682.566 | 677.311 | 667.389 |
Retained Earnings (Accumulated Deficit) | -573.336 | -545.361 | -516.992 | -470.038 | -438.358 |
Other Equity, Total | -0.22 | -0.212 | -0.211 | -0.167 | -0.16 |
Total Liabilities & Shareholders’ Equity | 139.282 | 159.736 | 179.088 | 225.69 | 242.646 |
Total Common Shares Outstanding | 17.7623 | 10.7623 | 10.19 | 12.2366 | 8.53144 |
Redeemable Preferred Stock | |||||
Other Current Assets, Total | |||||
Total Inventory | 13.317 | 13.7 | |||
Goodwill, Net | 0.965 | 0.965 | |||
Total Receivables, Net | 1.562 | ||||
Accounts Receivable - Trade, Net | 1.562 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | -110.218 | -92.287 | -50.463 | -28.618 | -26.089 |
Cash From Operating Activities | -98.053 | -75.557 | -48.566 | -26.683 | -23.971 |
Cash From Operating Activities | 1.253 | 0.05 | 0.027 | 0.026 | 0.054 |
Non-Cash Items | 10.914 | 10.899 | 4.236 | 1.457 | 1.627 |
Changes in Working Capital | -0.002 | 5.781 | -2.366 | 0.452 | 0.437 |
Cash From Investing Activities | -48.147 | -35.307 | -8.564 | -0.017 | -0.006 |
Capital Expenditures | -48.147 | -35.307 | -8.564 | -0.017 | -0.006 |
Other Investing Cash Flow Items, Total | 0 | ||||
Cash From Financing Activities | 87.844 | 212.487 | 123.105 | 12.919 | 23.539 |
Issuance (Retirement) of Stock, Net | 87.844 | 212.487 | 123.105 | 12.919 | 23.539 |
Foreign Exchange Effects | -0.074 | -0.031 | -0.016 | -0.004 | -0.013 |
Net Change in Cash | -58.43 | 101.592 | 65.959 | -13.785 | -0.451 |
Cash Taxes Paid | 0 | 0.082 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -33.005 | -110.218 | -78.538 | -49.557 | -26.417 |
Cash From Operating Activities | -32.911 | -98.053 | -75.752 | -52.217 | -31.046 |
Cash From Operating Activities | 0.893 | 1.253 | 0.417 | 0.165 | 0.063 |
Non-Cash Items | 2.794 | 10.914 | 8.198 | 5.433 | 2.62 |
Changes in Working Capital | -3.593 | -0.002 | -5.829 | -8.258 | -7.312 |
Cash From Investing Activities | -3.799 | -48.147 | -43.476 | -34.656 | -20.217 |
Capital Expenditures | -3.799 | -48.147 | -43.476 | -34.656 | -20.217 |
Cash From Financing Activities | -11.5 | 87.844 | 80.615 | 85.24 | 13.063 |
Issuance (Retirement) of Stock, Net | -11.5 | 87.844 | 80.615 | 85.24 | 13.063 |
Foreign Exchange Effects | -0.043 | -0.074 | -0.069 | -0.049 | -0.025 |
Net Change in Cash | -48.253 | -58.43 | -38.682 | -1.682 | -38.225 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Tonix Pharmaceuticals Holding Corp. Company profile
Tonix Pharmaceuticals Holding Corp. (TNXP) is a clinical-stage biopharmaceutical company that focuses on understanding diseases and developing innovative therapies with the potential to address unmet needs.
Headquartered in Chatham, New Jersey, Tonix Pharma was founded in 2007 with the idea of developing a diverse yet curated portfolio of small molecule drugs across various therapeutic areas, like the central nervous system (CNS), immunology, infectious disease and rare diseases. With a significant investment in in-house research and development and manufacturing, Tonix Pharma accelerates the drug development and reachability timeline and can respond immediately in case of an infectious disease breakout.
The company’s CNS portfolio comprises TNX-102 SL (Confirmatory Phase 3) for Fibromyalgia. Drugs in phase 2 development are TNX-102 SL for Posttraumatic Stress Disorder (PTSD), TNX-102 SL for long Covid, TNX-1300 for cocaine overdose and TNX-1900 for chronic migraine. It also has two drugs in the preclinical phase: TNX-1500 for organ transplant rejection/autoimmune disorders and TNX-1700 for gastric and colorectal cancers.
Pathogenic infections like smallpox and monkeypox have been a core area of focus for Tonix for a long time, however, the Covid-19 outbreak pushed the company to focus on rapid preparedness to combat infectious diseases. The company has the TNX-1840/1850 Covid-19 vaccine, TNX-3500 Covid-19 antiviral, TNX-3600 Covid-19 therapeutic and TNX-801 smallpox and monkeypox vaccine under development and in preclinical stages.
Tonix’s rare disease portfolio includes TNX-2900 for Prader-Willi syndrome, which is in the preclinical stage.
Tonix shares began trading under the ticker symbol ‘TNXP’ on the Nasdaq Capital Market in August 2013.
Industry: | Bio Therapeutic Drugs |
26 Main Street, Suite 101
CHATHAM
NEW JERSEY 07928
US
Income Statement
- Annual
- Quarterly
News
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024Four reasons why Bitcoin is surging to record highs
Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.
10:18, 14 March 2024China’s National People’s Congress: The markets have again been left wanting more
China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.
08:23, 8 March 2024Central Banks: which one will cut first?
Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut
13:14, 6 March 2024Nvidia (NVDA) confronts high expectations for Q4 results
Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.
12:13, 20 February 2024People also watch
Still looking for a broker you can trust?
Join the 580.000+ traders worldwide that chose to trade with Capital.com